	Application No.	Applicant(s)
•	10/624,154	SCHNEIDINGER ET AL.
Notice of Allowability	Examiner	Art Unit
	Tekchand Saidha	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. ☑ This communication is responsive to <u>21 July 2003</u> .		
2. The allowed claim(s) is/are <u>1-8 and 11</u> .		
3. A The drawings filed on 21 July 2003 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Summary Paper No./Mail Date 8), 7. Examiner's Amendre	e

Application/Control Number: 10/624,154

Art Unit: 1652

Notice of Allowability

- 1. Applicants' preliminary amendment filed July 21, 2003 is acknowledged.
- 2. Claims 1-8 & 11 are pending and under consideration in this examination.
- 3. Claims **1-8 & 11** are allowed.
- 4. The following is an examiner's statement of reasons for allowance:

The Application provides a unobvious conjugate of unglycosylated tissue non specific alkaline phosphatase (tns-AP) comprising the sequence of SEQ ID NO: 4 (residues 18-504) and dextran. Method(s) for making and using the product are also provided. The alkaline phosphatase sequence is a known sequence [see J. Biochem. 126: 694-699, 1999, Applicants' IDS), and dextran has been used in conjugating a variety of molecules. However, no prior reference taken alone or in combination either teach, suggest or provide motivation to one of ordinary skill in the art to use the skills available in the area of enzymology or molecular biology or make obvious the claimed tns-AP-dextran conjugate or methods of making and using the conjugate.

- 5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571) 272 0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 10/624,154

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 3

Tekchand Saidha

Primary Examiner, Art Unit 1652

Recombinant Enzymes, E03A61 Remsen Bld.

400 Dulany Street, Alexandria, VA

Telephone: (571) 272-0940

February 4, 2005